Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-II
Author:
Funder
Merck
DeLOS
Interdisciplinary Head and Neck Study Group
German Cancer Society
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/29/10/2105/26468731/mdy332.pdf
Reference24 articles.
1. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer;The Department of Veterans Affairs Laryngeal Cancer Study Group;N Engl J Med,1991
2. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group;Chevalier;J Natl Cancer Inst,1996
3. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer;Pfister;J Clin Oncol,2006
4. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer;Forastiere;J Clin Oncol,2013
5. Total laryngectomy versus larynx preservation for T4a larynx cancer: patterns of care and survival outcomes;Grover;Int J Radiat Oncol Biol Phys,2015
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The European Larynx Organ Preservation Study [MK-3475-C44];Frontiers in Oncology;2024-08-22
2. Is precision medicine the solution to improve organ preservation in laryngeal/hypopharyngeal cancer? A position paper by the Preserve Research Group;Frontiers in Oncology;2024-08-06
3. Improved survival of locoregional-advanced larynx and hypopharynx cancer patients treated according to the DeLOS-II protocol;Frontiers in Oncology;2024-06-11
4. Identification of Down-Expressed CRNN Associated with Cancer Progression and Poor Prognosis in Laryngeal Squamous Cell Carcinoma;Frontiers in Bioscience-Landmark;2024-03-22
5. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial;Nature Communications;2024-03-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3